Table 3.
Riociguat exposure data at steady state following multiple doses (individual dose adjustment up to 2.5 mg three times daily) of riociguat in PATENT-1 and CHEST-1
| Riociguat pharmacokinetic parameter | Patients with PAH: PATENT-1 study (n = 228) | Patients with CTEPH: CHEST-1 study (n = 153) |
|---|---|---|
| AUCT (µg·h/L) | ||
| Geometric mean (CV) | 1174 (55.0) | 1433 (45.2) |
| Median | 1226 | 1475 |
| C max (µg/L) | ||
| Geometric mean (CV) | 176 (47.8) | 207 (38.9) |
| Median | 178 | 213 |
| C trough (µg/L) | ||
| Geometric mean (CV) | 113 (69.6) | 145 (58.4) |
| Median | 124 | 152 |
AUC T area under the plasma concentration–time curve at steady state, C max maximum concentration in plasma, CTEPH chronic thromboembolic pulmonary hypertension, C trough minimum concentration in plasma, CV coefficient of variation, PAH pulmonary arterial hypertension